[{"orgOrder":0,"company":"Oranomed","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Licensing Agreement","leadProduct":"212-Pb Dotamtate","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Oranomed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oranomed \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Oranomed \/ Sanofi"},{"orgOrder":0,"company":"Oranomed","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Oranomed","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Oranomed \/ Sanofi","highestDevelopmentStatusID":"4","companyTruncated":"Oranomed \/ Sanofi"},{"orgOrder":0,"company":"Oranomed","sponsor":"Molecular Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"MP0712","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Oranomed","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oranomed \/ Molecular Partners","highestDevelopmentStatusID":"4","companyTruncated":"Oranomed \/ Molecular Partners"},{"orgOrder":0,"company":"Oranomed","sponsor":"Crescendo Biologics Ltd","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Oranomed","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Oranomed \/ Crescendo Biologics Ltd","highestDevelopmentStatusID":"4","companyTruncated":"Oranomed \/ Crescendo Biologics Ltd"},{"orgOrder":0,"company":"Oranomed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2023","type":"Inapplicable","leadProduct":"212-Pb DOTAM-GRPR1","moa":"GRPr","graph1":"Oncology","graph2":"Phase I","graph3":"Oranomed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oranomed \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Oranomed \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by Oranomed

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : Sanofi will be responsible for the global commercialization of AlphaMedix (212Pb-DOTAMTATE), while Orano will manufacture AlphaMedix through its global industrial platform currently under development.

                          Product Name : Alphamedix

                          Product Type : Peptide

                          Upfront Cash : $111.6 million

                          December 09, 2024

                          Lead Product(s) : 212-Pb Dotamtate

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Sanofi

                          Deal Size : $357.1 million

                          Deal Type : Licensing Agreement

                          blank

                          02

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : The agreement aims to combine Sanofi and Orano's expertise against rare cancers and accelerate the development of next-generation radioligand medicines based on 212Pb alpha-emitting isotopes.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          October 17, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery

                          Sponsor : Sanofi

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          03

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : The collaboration focuses on exemplify the benefit of Orano Med’s Targeted Alpha Therapies, using Humabody VH for precise targeting.

                          Product Name : Undisclosed

                          Product Type : Other Large Molecule

                          Upfront Cash : Undisclosed

                          July 07, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Crescendo Biologics Ltd

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          04

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : The Collaboration focuses on developing novel Radio-DARPin therapeutics (RDTs) that use Orano Med’s 212Pb radioisotope as a payload to kill cancer cells selectively.

                          Product Name : MP0712

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          May 01, 2024

                          Lead Product(s) : MP0712

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Molecular Partners

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          05

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : 212Pb-GRPR is a 212Pb-conjugated anti-GRPR (Gastrin-Releasing Peptide Receptor) targeting different types of solid tumors including several breast and prostate cancers tumor types.

                          Product Name : 212-Pb DOTAM-GRPR1

                          Product Type : Radiolabelled Compounds

                          Upfront Cash : Inapplicable

                          April 01, 2023

                          Lead Product(s) : 212-Pb DOTAM-GRPR1

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank